CRISPR-Cas-amplified urinary biomarkers for multiplexed and portable cancer diagnostics
Open accessThe DOI matches its Crossref record; 15 of the 15 references it cites were found in a registry or an index.
Abstract
Synthetic biomarkers, bioengineered sensors that generate molecular reporters in diseased microenvironments, represent an emerging paradigm in precision diagnostics. Despite the utility of DNA barcodes as a multiplexing tool, their susceptibility to nucleases in vivo has limited their utility. Here we exploit chemically stabilized nucleic acids to multiplex synthetic biomarkers and produce diagnostic signals in biofluids that can be ‘read out’ via CRISPR nucleases. The strategy relies on microenvironmental endopeptidase to trigger the release of nucleic acid barcodes and polymerase-amplification-free, CRISPR-Cas-mediated barcode detection in unprocessed urine. Our data suggest that DNA-encoded nanosensors can non-invasively detect and differentiate disease states in transplanted and autochthonous murine cancer models. We also demonstrate that CRISPR-Cas amplification can be harnessed to convert the readout to a point-of-care paper diagnostic tool. Finally, we employ a microfluidic platform for densely multiplexed, CRISPR-mediated DNA barcode readout that can potentially evaluate complex human diseases rapidly and guide therapeutic decisions.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Hallmarks of Cancer: New Dimensions
Hanahan, D. (2022) · Cancer Discovery · doi:10.1158/2159-8290.cd-21-1059 · Cited by 9,887
Microenvironmental regulation of tumor progression and metastasis
Quail, D. F., & Joyce, J. A. (2013) · Nature Medicine · doi:10.1038/nm.3394 · Cited by 7,994 · cited 1×
“…synthetic urine biomarkers (DNA-SUBs) (1) target diseased sites in vivo, (2) sense dysregulated proteolysis in the tumour microenvironment 21,22 , and (3) emit nucleic acid barcodes that survive circulation and are size-concentrated by the kidney 23–25 to (4) activate single-stranded…”
Anomalous collapses of Nares Strait ice arches leads to enhanced export of Arctic sea ice
Moore, G. W. K., Howell, S. E. L., Brady, M., Xu, X., & McNeil, K. (2021) · Nature Communications · doi:10.1038/s41467-020-20314-w · Cited by 5,155
CRISPR-Cas12a target binding unleashes indiscriminate single-stranded DNase activity
Chen, J. S., Ma, E., Harrington, L. B., Da Costa, M., Tian, X., Palefsky, J. M., & Doudna, J. A. (2018) · Science · doi:10.1126/science.aar6245 · Cited by 4,507 · cited 3×
“To multiplex synthetic biomarkers for use as point-of-care (PoC) precision diagnostics, we exploited chemically stabilized DNA for molecular barcoding and employed CRISPR-Cas nucleases for a sequence-specific readout 20 .”
Nanobodies: natural single-domain antibodies
Muyldermans, S. (2013) · Annual Review of Biochemistry · doi:10.1146/annurev-biochem-063011-092449 · Cited by 2,304
TGFβ drives immune evasion in genetically reconstituted colon cancer metastasis
Tauriello, D. V. F., Palomo-Ponce, S., Stork, D., Berenguer-Llergo, A., Badia-Ramentol, J., Iglesias, M., Sevillano, M., Ibiza, S., Cañellas, A., Hernando-Momblona, X., et al. (2018) · Nature · doi:10.1038/nature25492 · Cited by 1,851 · cited 1×
“We improved their on-target rate with functional biologics that can be extended to scaffolds with therapeutic efficacy, making it possible for combined therapy and diagnostics to monitor treatment responses in real time 51 .”
Current and future perspectives of liquid biopsies in genomics-driven oncology
Heitzer, E., Haque, I. S., Roberts, C. E. S., & Speicher, M. R. (2019) · Nature Reviews Genetics · doi:10.1038/s41576-018-0071-5 · Cited by 1,557
Genome-wide cell-free DNA fragmentation in patients with cancer
Cristiano, S., Leal, A., Phallen, J., Fiksel, J., Adleff, V., Bruhm, D. C., Jensen, S. Ø., Medina, J. E., Hruban, C., White, J. R., et al. (2019) · Nature · doi:10.1038/s41586-019-1272-6 · Cited by 1,476 · cited 2×
“Even measurements of endogenous, cell-free nucleic acids are hampered by sequence degradation when not protected by the nucleosome in circulation 12–16 .”
Naba, A., Clauser, K. R., Hoersch, S., Liu, H., Carr, S. A., & Hynes, R. O. (2012) · Molecular & Cellular Proteomics · doi:10.1074/mcp.m111.014647 · Cited by 1,354 · cited 4×
“For in vivo validation, we tested the PLAU-activated, cMET-targeting nanobody in the cMET-and PLAU-expressing PC-3-cell-derived tumour model (Supplementary Fig.”
InfluentialOverview of the Matrisome--An Inventory of Extracellular Matrix Constituents and Functions
Hynes, R. O., & Naba, A. (2012) · Cold Spring Harbor Perspectives in Biology · doi:10.1101/cshperspect.a004903 · Cited by 1,349 · cited 1×
“Matrisome proteomic analysis confirmed protease expression in primary CRCs and their distant metastases (for example, MMP-7, MMP-9, Cathepsin D, PLAU) 40,41 (Supplementary Fig.”
Metadata
- Authors
- Hao, L., Zhao, R. T., Welch, N. L., Tan, E. K. W., Zhong, Q., Harzallah, N. S., Ngambenjawong, C., Ko, H., Fleming, H. E., Sabeti, P. C., & Bhatia, S. N.
- Venue
- Nature Nanotechnology
- Published
- 2023-04-24
- Volume
- 18
- Issue
- 7
- Pages
- 798-807
- ISSN
- 1748-3387 (ISSN-L)
- 1748-3395
- OpenAlex
- W4366824220
- Cited by
- 163
- References
- 15
- FWCI
- 11.95
- Type
- journal article
- Language
- en
- Open access
- hybrid
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: CRISPR-Cas-amplified urinary biomarkers for multiplexed and portable cancer diagnostics. https://app.cochat.ai/papers/10.1038/s41565-023-01372-9
- The paper
- Hao, L., Zhao, R. T., Welch, N. L., Tan, E. K. W., Zhong, Q., Harzallah, N. S., Ngambenjawong, C., Ko, H., Fleming, H. E., Sabeti, P. C., & Bhatia, S. N. (2023). CRISPR-Cas-amplified urinary biomarkers for multiplexed and portable cancer diagnostics. Nature Nanotechnology. https://doi.org/10.1038/s41565-023-01372-9
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.